Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RKDA vs DXR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)

DXR Overall Winner 6-Pillar Tally: RKDA 2 – 3 DXR (1 Tie) Matrix Metrics: RKDA 2 – 7 DXR

As of Nov 16, 2026, Daxor Corporation (DXR) is the stronger overall head-to-head candidate over Arcadia Biosciences, Inc. (RKDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RKDA carries a Unified Composite Score of 28.0/100 (SELL) at $0.19 (36.6x Forward P/E, -80.2% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin).

  • Technical & Structure Timing Caution: RKDA is currently in a Breakdown options structure phase (RSI 45.8); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RKDA vs DXR
RKDA NASDAQ
Arcadia Biosciences, Inc.
Crude Petroleum & Natural Gas
$0.19
-11.19% 1D
Market Cap $1.3M
TTM Revenue $4.7M
Forward P/E 36.6x
Beta / 30D Vol 1.27β · 170% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 5.0 Fund 46.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.8 · SMA20: $0.17 · SMA50: $0.27
DXR NASDAQ Head-to-Head Winner
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07

6-Pillar Scorecard Institutional Category Breakdown (RKDA 2 – 3 DXR)

Columns: Metric · RKDA · DXR
1. Valuation Multiples RKDA
Forward P/E 36.6x 64.5x
Trailing P/E 36.6x 7.7x
PEG Ratio N/M N/M
EV / Revenue 0.3x N/M
2. Growth & Scale DXR
Revenue Growth (YoY) -0.8% +25.5%
Earnings Growth (YoY) +28.5% +329.3%
TTM Revenue (USD) $4.7M $31,360
Market Cap $1.3M $49.5M
3. Profitability & Quality DXR
Gross Margin 34.6% 100.0%
Operating Margin -80.2% -5894.3%
Net Profit Margin -234.5% 19861.4%
Return on Equity (ROE) -430.9% 14.2%
4. Balance Sheet & Cash Flow RKDA
Cash Generation (TTM) -$3.8M EBITDA N/A
Cash Flow Margin -79.9% EBITDA Mgn N/A
Net Cash / Leverage $3.02 Book/Sh · -430.9% ROE $8.88 Book/Sh · 14.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DXR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Packaged Foods Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RKDA (2) vs DXR (7)
Institutional Metric RKDA DXR Criterion Row Edge
Market Capitalization
Scale
$1.3M $49.5M Larger Scale DXR
Trailing P/E Ratio
Valuation
36.6x 7.7x Lower Multiple DXR
Forward P/E Ratio
Valuation
36.6x 64.5x Lower Multiple RKDA
Revenue Growth (YoY)
Growth
-0.8% +25.5% Higher Growth DXR
Operating Margin (TTM)
Profitability
-80.2% -5894.3% Higher Margin RKDA
Net Profit Margin
Profitability
-234.5% 19861.4% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
-430.9% 14.2% Higher ROE DXR
52-Week Range Position
Momentum
2% ($0–$4) 2% ($8–$15) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.27β · 170% Vol 0.28β · 32% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
28.0 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$4.7M $31,360 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.6% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.8M EBITDA ($3.02 Book/Sh · -430.9% ROE) N/A ($8.88 Book/Sh · 14.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RKDA +34.35 pp
RKDA: +17.48% · DXR: -16.87%
3M Horizon DXR +46.37 pp
RKDA: -66.03% · DXR: -19.66%
6M Horizon DXR +66.43 pp
RKDA: -83.87% · DXR: -17.44%
1Y Horizon DXR +61.71 pp
RKDA: -94.98% · DXR: -33.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RKDA vs DXR. Trailing 12-month operating profitability (RKDA -80.2% vs DXR -5894.3%) and valuation multiples (RKDA 36.6x vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.

RKDA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.7M
Gross Margin34.6%
Op. Margin-80.2%
ROE / Fwd P/E-430.9% · 36.6x
DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RKDA BREAKDOWN
53d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact RKDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RKDA Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $1.3M market capitalization and -80.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RKDA vs DXR Key Questions & Quantitative Answers

As of Nov 16, 2026, Daxor Corporation (DXR) is the stronger overall head-to-head candidate over Arcadia Biosciences, Inc. (RKDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RKDA carries a Unified Composite Score of 28.0/100 (SELL) at $0.19 (36.6x Forward P/E, -80.2% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Technical & Structure Timing Caution: RKDA is currently in a Breakdown options structure phase (RSI 45.8); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: RKDA posts -0.8% YoY revenue growth and +28.5% YoY earnings growth on $4.7M TTM revenue (34.6% gross margin, -80.2% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, RKDA generates $4.7M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, RKDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.

RKDA screens cheaper on headline valuation multiples. RKDA trades at 36.6x Forward P/E, 36.6x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-79.9% EBITDA margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RKDA (-430.9% ROE) versus DXR (14.2% ROE) capital efficiency.

In options market volatility and institutional positioning, RKDA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.27β · 170% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.